An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART

Trial Profile

An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Romidepsin (Primary) ; Vacc-4x (Primary) ; Sargramostim
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REDUC
  • Sponsors Bionor Holding; Bionor Pharma
  • Most Recent Events

    • 07 Mar 2018 Results of analysis investigating the HIV phylogenetic composition of the four regions targeted by the the VAcc-4x presented at the 25th Conference on Retroviruses and Opportunistic Infections
    • 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
    • 26 Jul 2017 Results of a study assessing the phylogenetic relationship between circulating proviruses, stimulated outgrowth viruses and rebound viremia presented at the 9th International AIDS Society Conference on HIV Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top